Dr Reddy’s Laboratories Ltd, a Rs. 13,800 crore fifth largest pharma company, has launched US FDA approved levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR tablets in the United States market.

Levocetirizine dihydrochloride tablets USP, 5 mg is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing.

"This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” says Milan Kalawadia, vice president and head, US over-the-counter and speciality Rx businesses, Dr. Reddy’s Laboratories. “We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market.”

The Xyzal Allergy 24HR tablets brand had US sales of approximately $71 million for the most recent twelve months ending in January 2018 according to IRI.

Dr. Reddy’s levocetirizine dihydrochloride tablets USP is available in 5 mg strength and in various consumer oriented package sizes.

Xyzal is a registered trademark of UCB Group of companies.